Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

by @JTC_PALIdev | Mar 12, 2025 | Press Releases

PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Abstract was Rated in the Top 10% of all AGA Abstracts Selected for Poster Presentation at DDW Carlsbad, CA, March 12, 2025 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade...

Palisade Bio Participates in Virtual Investor “What This Means” Segment

by @JTC_PALIdev | Mar 4, 2025 | Press Releases

Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) Carlsbad, CA, March 04, 2025 — Palisade Bio, Inc. (Nasdaq: PALI)...

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

by @JTC_PALIdev | Feb 20, 2025 | Press Releases

Company through its co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit Program for PALI-2108 Ongoing progress of Palisade Bio’s Phase 1a/b UC...

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference

by @JTC_PALIdev | Feb 19, 2025 | Press Releases

On-demand video webcast now available here Carlsbad, CA, Feb. 19, 2025 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and...

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

by @JTC_PALIdev | Feb 10, 2025 | Press Releases

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a...

Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

by @JTC_PALIdev | Jan 29, 2025 | Press Releases

Carlsbad, CA, Jan. 29, 2025 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients...